DNLI
Denali Therapeutics Inc.
Price Chart
Latest Quote
$23.31
-0.18 (-0.77%)
Current Price
| Previous Close | $23.49 |
| Open | $24.16 |
| Day High | $24.65 |
| Day Low | $23.21 |
| Volume | 2,518,393 |
Stock Information
| Shares Outstanding | 158.71M |
| Total Debt | $40.05M |
| Cash Equivalents | $987.68M |
| Net Income | $-508.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.70B |
| EPS (TTM) | $-2.88 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.75B |
| Income | $-508.02M |
| Book/sh | $5.84 |
| Cash/sh | $6.22 |
| Employees | 507 |
Financial Ratios
| Quick Ratio | 8.98 |
| Current Ratio | 9.29 |
| Debt/Eq | 4.32 |
Returns & Margins
| ROA | -26.95% |
| ROE | -49.59% |
Ownership
| Insider Ownership | 9.16% |
| Institutional Ownership | 99.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.41 |
| P/B | 3.99 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $33.93 |
Technical Indicators
| SMA20 | $20.66 |
| SMA50 | $19.99 |
| SMA200 | $18.37 |
| RSI | 63.86 |
| ATR | 1.2366 |
| Shares Float | 144.23M |
| Short Float | 9.97% |
| Short Ratio | 7.54 |
| Volatility | 1.01 |
| Rel Volume | 1.29 |
Performance History
| Week | +10.89% |
| Month | +28.71% |
| Quarter | +18.03% |
| 6 Months | +36.96% |
| YTD | +43.27% |
| Year | +66.38% |
| 3 Years | -29.28% |
| 5 Years | -68.92% |
| 10 Years | +8.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $23.31 | 2,518,400 |
| 2026-06-17 | $23.49 | 2,605,200 |
| 2026-06-16 | $21.93 | 1,455,900 |
| 2026-06-15 | $22.22 | 1,448,800 |
| 2026-06-12 | $21.66 | 2,176,000 |
| 2026-06-11 | $21.02 | 1,964,800 |
| 2026-06-10 | $20.61 | 2,483,700 |
| 2026-06-09 | $20.79 | 1,916,900 |
| 2026-06-08 | $19.54 | 1,893,200 |
| 2026-06-05 | $19.52 | 2,192,200 |
| 2026-06-04 | $20.14 | 1,833,500 |
| 2026-06-03 | $19.66 | 1,027,100 |
| 2026-06-02 | $19.35 | 1,764,100 |
| 2026-06-01 | $20.41 | 1,678,900 |
| 2026-05-29 | $21.04 | 1,699,800 |
| 2026-05-28 | $20.95 | 1,354,500 |
| 2026-05-27 | $20.21 | 1,625,500 |
| 2026-05-26 | $19.38 | 2,354,200 |
| 2026-05-22 | $18.64 | 3,557,100 |
| 2026-05-21 | $19.30 | 1,351,500 |
| 2026-05-20 | $18.83 | 1,379,700 |
| 2026-05-19 | $18.11 | 2,130,800 |
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
đ° Latest News
Denali to Sell Priority Review Voucher for $195M Cash Boost
Zacks âĸ 2026-06-19T12:40:00Z
Pfizer CFO to step down; Denali sells a regulatory fast-pass
BioPharma Dive âĸ 2026-06-18T10:55:00Z
Acumen Nominates 2 Therapies to Treat Alzheimerâs Disease
Exec Edge âĸ 2026-06-16T22:18:17Z
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
Insider Monkey âĸ 2026-06-11T10:20:35Z
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline
Simply Wall St. âĸ 2026-06-02T10:07:31Z
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos
Insider Monkey âĸ 2026-06-01T17:12:41Z
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says
MT Newswires âĸ 2026-05-26T15:29:06ZStocks Settle Higher on Iran Peace Hopes and Tech Strength
Barchart âĸ 2026-05-22T20:34:34Z
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks
Simply Wall St. âĸ 2026-05-22T20:15:41Z
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Zacks âĸ 2026-05-22T16:14:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $330,531,000 | $108,463,000 |
| Operating Revenue | $0 | $0 | $330,531,000 | $105,065,000 |
| Expenses | ||||
| Total Expenses | $555,342,000 | $501,878,000 | $527,230,000 | $449,207,000 |
| Net Non Operating Interest Income Expense | $42,904,000 | $64,636,000 | $51,505,000 | $14,774,000 |
| Operating Expense | $555,342,000 | $501,878,000 | $527,230,000 | $449,207,000 |
| General And Administrative Expense | $136,564,000 | $105,438,000 | $103,354,000 | $90,475,000 |
| Other Income Expense | - | $14,537,000 | - | - |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
| Net Interest Income | $42,904,000 | $64,636,000 | $51,505,000 | $14,774,000 |
| Interest Income | $42,904,000 | $64,636,000 | $51,505,000 | $14,774,000 |
| Normalized Income | $-512,540,000 | $-434,257,230 | $-145,224,000 | $-325,991,000 |
| Net Income From Continuing And Discontinued Operation | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
| Total Operating Income As Reported | $-555,342,000 | $-487,341,000 | $-196,699,000 | $-340,744,000 |
| Net Income Common Stockholders | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
| Net Income | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
| Net Income Including Noncontrolling Interests | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
| Net Income Continuous Operations | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
| Pretax Income | $-512,438,000 | $-422,705,000 | $-145,194,000 | $-325,970,000 |
| Special Income Charges | $0 | $14,537,000 | $0 | $0 |
| Interest Income Non Operating | $42,904,000 | $64,636,000 | $51,505,000 | $14,774,000 |
| Operating Income | $-555,342,000 | $-501,878,000 | $-196,699,000 | $-340,744,000 |
| Per Share | ||||
| Diluted EPS | $-2.97 | $-2.57 | $-1.06 | $-2.60 |
| Basic EPS | $-2.97 | $-2.57 | $-1.06 | $-2.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $3,052,770 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-540,530,000 | $-507,423,000 | $-179,973,000 | $-330,361,000 |
| Total Unusual Items | $0 | $14,537,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $14,537,000 | $0 | $0 |
| Reconciled Depreciation | $14,812,000 | $8,992,000 | $16,726,000 | $10,383,000 |
| EBITDA (Bullshit earnings) | $-540,530,000 | $-492,886,000 | $-179,973,000 | $-330,361,000 |
| EBIT | $-555,342,000 | $-501,878,000 | $-196,699,000 | $-340,744,000 |
| Diluted Average Shares | $172,649,097 | $164,473,772 | $137,370,897 | $125,530,703 |
| Basic Average Shares | $172,649,097 | $164,473,772 | $137,370,897 | $125,530,703 |
| Diluted NI Availto Com Stockholders | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
| Tax Provision | $102,000 | $68,000 | $30,000 | $21,000 |
| Gain On Sale Of Business | $0 | $14,537,000 | $0 | $0 |
| Research And Development | $418,778,000 | $396,440,000 | $423,876,000 | $358,732,000 |
| Selling General And Administration | $136,564,000 | $105,438,000 | $103,354,000 | $90,475,000 |
| Other Gand A | $136,564,000 | $105,438,000 | $103,354,000 | $90,475,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,013,761,000 | $1,229,684,000 | $1,030,954,000 | $1,042,430,000 |
| Total Assets | $1,144,854,000 | $1,374,180,000 | $1,153,917,000 | $1,460,242,000 |
| Total Non Current Assets | $244,196,000 | $509,744,000 | $89,780,000 | $87,923,000 |
| Other Non Current Assets | $25,939,000 | $24,741,000 | $18,143,000 | $13,399,000 |
| Investmentin Financial Assets | $98,322,000 | $359,373,000 | $0 | $0 |
| Current Assets | $900,658,000 | $864,436,000 | $1,064,137,000 | $1,372,319,000 |
| Prepaid Assets | $30,602,000 | $29,934,000 | $26,206,000 | $26,822,000 |
| Receivables | $2,177,000 | $2,171,000 | $3,420,000 | $9,282,000 |
| Accounts Receivable | $2,177,000 | $2,171,000 | $3,420,000 | $9,282,000 |
| Cash Cash Equivalents And Short Term Investments | $867,879,000 | $832,331,000 | $1,034,511,000 | $1,336,215,000 |
| Cash And Cash Equivalents | $205,326,000 | $174,960,000 | $127,106,000 | $218,044,000 |
| Other Current Assets | - | - | - | $36,104,000 |
| Debt | ||||
| Total Debt | $36,756,000 | $48,707,000 | $52,241,000 | $60,350,000 |
| Long Term Debt And Capital Lease Obligation | $27,210,000 | $36,673,000 | $44,981,000 | $53,032,000 |
| Current Debt And Capital Lease Obligation | $9,546,000 | $12,034,000 | $7,260,000 | $7,318,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $131,093,000 | $144,496,000 | $122,963,000 | $417,812,000 |
| Total Non Current Liabilities Net Minority Interest | $32,742,000 | $42,288,000 | $44,981,000 | $53,890,000 |
| Other Non Current Liabilities | $5,532,000 | $5,615,000 | - | $379,000 |
| Current Liabilities | $98,351,000 | $102,208,000 | $77,982,000 | $363,922,000 |
| Current Deferred Liabilities | $21,101,000 | $14,129,000 | $0 | $290,053,000 |
| Payables And Accrued Expenses | $35,525,000 | $51,317,000 | $49,132,000 | $49,464,000 |
| Payables | $3,330,000 | $11,137,000 | $9,483,000 | $7,178,000 |
| Accounts Payable | $3,330,000 | $11,137,000 | $9,483,000 | $2,790,000 |
| Non Current Deferred Liabilities | - | - | $0 | $479,000 |
| Equity | ||||
| Common Stock Equity | $1,013,761,000 | $1,229,684,000 | $1,030,954,000 | $1,042,430,000 |
| Total Equity Gross Minority Interest | $1,013,761,000 | $1,229,684,000 | $1,030,954,000 | $1,042,430,000 |
| Stockholders Equity | $1,013,761,000 | $1,229,684,000 | $1,030,954,000 | $1,042,430,000 |
| Gains Losses Not Affecting Retained Earnings | $682,000 | $2,020,000 | $643,000 | $-6,886,000 |
| Other Equity Adjustments | $682,000 | $2,020,000 | $643,000 | $-6,886,000 |
| Retained Earnings | $-2,051,524,000 | $-1,538,984,000 | $-1,116,211,000 | $-970,987,000 |
| Other | ||||
| Ordinary Shares Number | $156,182,177 | $144,220,986 | $138,385,498 | $135,965,918 |
| Share Issued | $156,182,177 | $144,220,986 | $138,385,498 | $135,965,918 |
| Tangible Book Value | $1,013,761,000 | $1,229,684,000 | $1,030,954,000 | $1,042,430,000 |
| Invested Capital | $1,013,761,000 | $1,229,684,000 | $1,030,954,000 | $1,042,430,000 |
| Working Capital | $802,307,000 | $762,228,000 | $986,155,000 | $1,008,397,000 |
| Capital Lease Obligations | $36,756,000 | $48,707,000 | $52,241,000 | $60,350,000 |
| Total Capitalization | $1,013,761,000 | $1,229,684,000 | $1,030,954,000 | $1,042,430,000 |
| Additional Paid In Capital | $3,062,715,000 | $2,764,880,000 | $2,144,811,000 | $2,018,617,000 |
| Capital Stock | $1,888,000 | $1,768,000 | $1,711,000 | $1,686,000 |
| Common Stock | $1,888,000 | $1,768,000 | $1,711,000 | $1,686,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $27,210,000 | $36,673,000 | $44,981,000 | $53,032,000 |
| Current Capital Lease Obligation | $9,546,000 | $12,034,000 | $7,260,000 | $7,318,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $32,179,000 | $24,728,000 | $21,590,000 | $17,087,000 |
| Current Accrued Expenses | $32,195,000 | $40,180,000 | $39,649,000 | $42,286,000 |
| Investments And Advances | $98,322,000 | $359,373,000 | $0 | $0 |
| Net PPE | $119,935,000 | $125,630,000 | $71,637,000 | $74,524,000 |
| Accumulated Depreciation | $-62,895,000 | $-52,042,000 | $-46,003,000 | $-37,215,000 |
| Gross PPE | $182,830,000 | $177,672,000 | $117,640,000 | $111,739,000 |
| Leases | $47,755,000 | $46,905,000 | $41,238,000 | $43,698,000 |
| Other Properties | $130,823,000 | $126,946,000 | $72,755,000 | $64,856,000 |
| Machinery Furniture Equipment | $4,252,000 | $3,821,000 | $3,647,000 | $3,185,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $662,553,000 | $657,371,000 | $907,405,000 | $1,118,171,000 |
| Non Current Deferred Revenue | - | - | $0 | $479,000 |
| Current Deferred Revenue | - | - | $0 | $290,053,000 |
| Dueto Related Parties Current | - | - | $0 | $4,388,000 |
| Duefrom Related Parties Current | - | - | - | $0 |
| Other Investments | - | - | - | - |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-422,102,000 | $-363,606,000 | $-370,930,000 | $-262,549,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-412,600,000 | $-347,694,000 | $-357,991,000 | $-244,716,000 |
| Cash Flow From Continuing Operating Activities | $-412,600,000 | $-347,694,000 | $-357,991,000 | $-244,716,000 |
| Operating Gains Losses | - | $-14,537,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-9,502,000 | $-15,912,000 | $-12,939,000 | $-17,833,000 |
| Investing Cash Flow | $255,281,000 | $-88,756,000 | $249,308,000 | $-141,387,000 |
| Cash Flow From Continuing Investing Activities | $255,281,000 | $-88,756,000 | $249,308,000 | $-141,387,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $189,249,000 | $499,253,000 | $0 | $296,215,000 |
| Financing Cash Flow | $189,216,000 | $484,304,000 | $17,820,000 | $310,670,000 |
| Cash Flow From Continuing Financing Activities | $189,216,000 | $484,304,000 | $17,820,000 | $310,670,000 |
| Net Other Financing Charges | $-324,000 | - | - | - |
| Net Common Stock Issuance | $189,249,000 | $499,253,000 | $0 | $296,215,000 |
| Common Stock Issuance | $189,249,000 | $499,253,000 | $0 | $296,215,000 |
| Other | ||||
| Repayment Of Debt | $-8,168,000 | $-32,338,000 | $0 | $0 |
| Interest Paid Supplemental Data | $720,000 | $302,000 | $0 | - |
| Income Tax Paid Supplemental Data | $46,000 | $0 | $3,000 | $47,000 |
| End Cash Position | $208,432,000 | $176,535,000 | $128,681,000 | $219,544,000 |
| Beginning Cash Position | $176,535,000 | $128,681,000 | $219,544,000 | $294,977,000 |
| Changes In Cash | $31,897,000 | $47,854,000 | $-90,863,000 | $-75,433,000 |
| Proceeds From Stock Option Exercised | $8,459,000 | $17,389,000 | $17,820,000 | $14,455,000 |
| Net Issuance Payments Of Debt | $-8,168,000 | $-32,338,000 | $0 | $0 |
| Net Long Term Debt Issuance | $-8,168,000 | $-32,338,000 | $0 | $0 |
| Long Term Debt Payments | $-8,168,000 | $-32,338,000 | $0 | $0 |
| Net Investment Purchase And Sale | $264,783,000 | $-72,844,000 | $262,247,000 | $-123,554,000 |
| Sale Of Investment | $706,046,000 | $1,157,120,000 | $2,075,947,000 | $991,486,000 |
| Purchase Of Investment | $-441,263,000 | $-1,229,964,000 | $-1,813,700,000 | $-1,115,040,000 |
| Net PPE Purchase And Sale | $-9,502,000 | $-15,912,000 | $-12,939,000 | $-17,833,000 |
| Purchase Of PPE | $-9,502,000 | $-15,912,000 | $-12,939,000 | $-17,833,000 |
| Change In Working Capital | $149,000 | $16,937,000 | $-289,926,000 | $-24,030,000 |
| Change In Other Working Capital | $6,972,000 | $14,129,000 | $-290,532,000 | $-34,462,000 |
| Change In Other Current Liabilities | $0 | $0 | $-379,000 | $0 |
| Change In Other Current Assets | $772,000 | $603,000 | $0 | $0 |
| Change In Payables And Accrued Expense | $-7,055,000 | $4,685,000 | $5,079,000 | $13,192,000 |
| Change In Accrued Expense | $465,000 | $3,248,000 | $2,648,000 | $10,918,000 |
| Change In Payable | $-7,520,000 | $1,437,000 | $2,431,000 | $2,274,000 |
| Change In Account Payable | $-7,520,000 | $1,437,000 | $2,431,000 | $2,274,000 |
| Change In Prepaid Assets | $-540,000 | $-2,480,000 | $-4,094,000 | $-2,760,000 |
| Other Non Cash Items | $-4,401,000 | $-4,074,000 | $-3,717,000 | $-3,288,000 |
| Stock Based Compensation | $99,633,000 | $102,878,000 | $108,102,000 | $99,847,000 |
| Amortization Of Securities | $-10,253,000 | $-35,117,000 | $-43,952,000 | $-1,637,000 |
| Depreciation Amortization Depletion | $14,812,000 | $8,992,000 | $16,726,000 | $10,383,000 |
| Depreciation And Amortization | $14,812,000 | $8,992,000 | $16,726,000 | $10,383,000 |
| Depreciation | $14,812,000 | $8,992,000 | $16,726,000 | $10,383,000 |
| Gain Loss On Sale Of Business | $0 | $-14,537,000 | $0 | $0 |
| Net Income From Continuing Operations | $-512,540,000 | $-422,773,000 | $-145,224,000 | $-325,991,000 |
Fetched: 2026-06-16